4-Sep-2026
Quanterix Names Jim Gute Chief Commercial Officer
Business Wire (Mon, 10-Aug 8:01 AM ET)
Quanterix Releases Financial Results for the Second Quarter of 2026
Business Wire (Mon, 10-Aug 8:00 AM ET)
Business Wire (Thu, 6-Aug 8:00 AM ET)
Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026
Business Wire (Tue, 4-Aug 8:00 AM ET)
Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Thu, 16-Jul 4:05 PM ET)
Business Wire (Tue, 14-Jul 4:29 PM ET)
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Tue, 16-Jun 4:01 PM ET)
Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer
Business Wire (Tue, 9-Jun 8:03 AM ET)
Quanterix's Multi-Analyte FDA Submission Could Redefine Alzheimer's Diagnosis
Market Chameleon (Tue, 3-Feb 4:39 AM ET)
QTRX Announces CEO Transition With Everett Cunningham, Exceeds 2025 Revenue Outlook
Market Chameleon (Fri, 9-Jan 6:13 AM ET)
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.
Quanterix trades on the NASDAQ stock market under the symbol QTRX.
As of September 4, 2026, QTRX stock price climbed to $2.69 with 266,838 million shares trading.
QTRX has a beta of 0.98, meaning it tends to be less sensitive to market movements. QTRX has a correlation of 0.02 to the broad based SPY ETF.
QTRX has a market cap of $127.22 million. This is considered a Micro Cap stock.
Last quarter Quanterix reported $33 million in Revenue and -$.47 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.09.
In the last 3 years, QTRX traded as high as $29.70 and as low as $2.15.
The top ETF exchange traded funds that QTRX belongs to (by Net Assets): VTI, VXF, VTWO, FESM, SCHA.
QTRX has underperformed the market in the last year with a price return of -37.7% while the SPY ETF gained +19.8%. QTRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -29.2% and -10.0%, respectively, while the SPY returned +2.0% and +0.6%, respectively.
QTRX support price is $2.41 and resistance is $2.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QTRX shares will trade within this expected range on the day.